MicroDose Therapeutx and Nexus6 have entered into a non-exclusive agreement where by MicroDose will be able to provide its electronic dry powder inhaler (DPI) with Nexus6's SmartinhalerLive technology built in.
As a result of current agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and reporting.
MicroDose said that the data collection and global roaming wireless capability of SmartinhalerLive complements its electronic inhaler features thus facilitating better communication between the physician, patient and pharmaceutical company to improve all aspects of care.
MicroDose Business Development and Licensing VP Michael Martin said that the combination of Nexus6 Technology and MicroDose’s dry powder inhaler will insure a continuous flow of ‘real time’ clinical information which will benefit physicians, patients and pharmaceutical companies.
Nexus6 CEO David Evans said that this partnership will enable the drug delivery marketplace to access edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall health care costs.